Direct to confusion: Lessons learned from marketing BRCA testing

American Journal of Bioethics

Volumn 8, Issue 6, 2008, Pages 5-8

  Matloff, Ellen ^a   Caplan, Arthur ^b  

^a YALE CANCER CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

BRCA1; BRCA2; Genetic testing; Hereditary breast and ovarian cancer; Monopoly; Myriad Genetics; Patents

Indexed keywords

BIOTECHNOLOGY; BREAST TUMOR; ECONOMICS; ETHICS; FEMALE; FINANCIAL MANAGEMENT; GENETIC COUNSELING; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; HEALTH CARE DELIVERY; HUMAN; LEGAL LIABILITY; ORGANIZATION AND MANAGEMENT; OVARY TUMOR; PATENT; PUBLIC HEALTH; REVIEW; SOCIAL MARKETING; TUMOR SUPPRESSOR GENE; UNITED STATES;

BIOTECHNOLOGY; BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HEALTH SERVICES ACCESSIBILITY; HUMANS; LIABILITY, LEGAL; MARKETING OF HEALTH SERVICES; OVARIAN NEOPLASMS; PATENTS AS TOPIC; PRIVATE SECTOR; PUBLIC HEALTH; SOCIAL MARKETING; UNITED STATES;

EID: 50149111390     PISSN: 15265161     EISSN: 15360075     Source Type: Journal    
DOI: 10.1080/15265160802248179     Document Type: Review

References (33)

1. American College of Medical Genetics. 2004. ACMG statement on direct-to-consumer genetic testing. Genetics in Medicine 6(1): 60.
2. Antoniou, A., Gayther, S., Stratton, J. F., Ponder, B. A., and Easton, D. F. 2000. Risk models for familial ovarian and breast cancer. Cancer Epidemiology, Biomarkers, and Prevention 13:2078-2083.
3. Associated Press 2007. Myriad Genetics stock hits new high. Available at: http://news.moneycentral.msn.com/ticker/article.aspx?symbol=US: MYGN&feed=AP&date=20071001&id=7560073 (accessed June 17, 2008).
4. Baars, M., Henneman, L., and Kate, L. P. T. 2005. Deficiency of knowledge of genetics and genetic tests among general practitioners, gynecologists, and pediatricians: A global problem. Genetics in Medicine 7(9): 605-610.
5. Caplan, A. 2007. Smart mice, not so smart people: An interesting and amusing guide to bioethics. Lanham, MD: Rowman & Littlefield.
6. Domchek, S., Friebel, T., Neuhausen, S. L., Wagner, T., Evans, G., and Isaacs, C. 2006. Mortality reduction after risk-reducing bilateral salpingo-oophorectomy in a prospective cohort of BRCA1 and BRCA2 mutation carriers. Lancet Oncology 7(3): 223-229.
7. Ford, D., Easton, D., and Bishop, D.T. 1994. Risks of cancer in BRCA1 mutation carriers. Lancet 343:692-695.
8. Giardiello, F., Brensinger, J., and Petersen, G. M. 1997. The use and interpretation of commercial APC gene testing for familial adenomatous polyposis. New England Journal of Medicine 336:823-827.
9. Gollust, S., Hull, S., and Wilfond, B. S. 2002. Limitations of direct-to-consumer advertising for clinical genetic testing. Journal of the American Medical Association 288(14): 1762-1767.
10. Gray, S., and O. Olopade 2003. Direct-to-consumer marketing of genetic tests for cancer: Buyer beware. Journal of Clinical Oncology 21:3191.
11. Hall, J., Lee, M., Newman, B., Morrow, J. E., Anderson, L. A., and Huey, B. 1990. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 250(4988): 1684-1689.
12. Hull, S., and K. Prasad 2001. Reading between the lines: Direct-to-consumer advertising of genetic testing. Hastings Center Report 3:33.
13. Javitt, G., and K. Hudson 2006. Federal neglect: Regulation of genetic testing. Issues in Science and Technology 22(3): 59-66.
14. King, M., Marks, J., Mandell, J. B., and New York Breast Study Group. 2003. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302(5645): 643-646.
15. Lerman, C., Rimer, B., and Engstrom, P. F. 1991. Cancer risk notification: Psychosocial and ethical implications. Journal of Clinical Oncology 9(7): 1275-1282.
16. Matthijs, G. 2006. The European opposition against the BRCA gene patents. Familial Cancer 5:95-102.
17. Myers, M., Chang, M., Jorgensen, C., Whitworth, W., Kassim, S., and Litch, J. A. 2006. Genetic testing for susceptibility to breast and ovarian cancer: evaluating the impact of a direct-to-consumer marketing campaign on physicians' knowledge and practices. Genetics in Medicine 8(6): 361-370.
18. Myriad Genetics, Inc. 2007a. Myriad Genetics launches awareness advertising campaign to educate women about hereditary risks of breast and ovarian cancers. http://www.myriad.com/news/release/1049527 (accessed 11 September 2007).
19. Myriad Genetics, Inc. 2007b. Our careers. http//www.myriad.com/careers/ job/4300-1567 (accessed 3 August 2007).
20. Myriad Genetics, Inc. 2008. BRACA analysis: Be ready against cancer. http://www.bracnow.com/ (accessed 7 July 2008).
21. Myriad Genetics, Inc. 2008. Myriad Genetics reports results for second quarter of fiscal 2008: Molecular diagnostics revenues increase 55%, gross profits up 70%. Available at: myriad.com/news/release/1104224 (accessed 1 October 2007).
22. Pollack, A. 2007. A genetic test that very few need, marketed to the masses. The New York Times: C3.
23. Rebbeck, T., Friebel, T., Lynch, H. T., Neuhausen, S. L., vant' Veer, L., Garber, J. E. 2004. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: The PROSE Study Group. Journal of Clinical Oncology 22(6).
24. Ries, L., Melbert, D., Krapcho, M., Mariotto, A., Miller, B. A., and Feuer, E. J. 2007. SEER cancer statistics review, 1975-2004. Bethesda, MD: National Cancer Institute.
25. Rogers, D. 2008. Tests find cancer infrequently hereditary, Dr. Beth Young Karlan tells Hearing the Ovarian Cancer Whisper group. www.palmbeachdailynews.com/news/content/news/HOWtalk0315.html (accessed 15 May 2008).
26. Sevilla, C., Julian-Peynier, C., Eisinger, F., Stoppa-Lyonnet, D., Bressaco-dePaillerets, B., and Sobol, H. 2003. Impact of gene patents on the cost-effective delivery of care: the case of BRCA1 genetic testing. International Journal of Technology Assessment in Health Care 19(2): 287-300.
27. Watson, E. 1999. The new genetics and primary care: GP's views on their role and their educational needs. Family Practice 16: 420-425.
28. Wideroff, L. 2005. Hereditary breast/ovarian and colorectal cancer genetics knowledge in a national sample of US physicians. Journal of Medical Genetics 42: 749-755.
29. Wilkins-Haug, L., Erickson, K., Hill, L., Power, M., Holzman, G. B., and Schulkin, J. 2000. Obstetrician-Gynecologist's opinions and attitudes on the role of genetics in women's health. Journal of Women's Health & Gender-Based Medicine 9(8): 873-879.
30. Williams-Jones, B. 2002. History of a gene patent: Tracing the development and application of commercial BRCA testing. Health Law Journal 10: 123-146.
31. Williams-Jones, B. 2006. Be ready against cancer, now: direct-to-consumer advertising for genetic testing. New Genetics and Society 25(1): 89-107.
32. Wooster, R., Neuhausen, S., Mangion, J., Quirk, Y., Ford, D., and Collins, N. 1994. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 265(5181): 2088-2090.
33. Zielinski, S. 2004. BRCA1 discovery led to patent debate, genetic screening. Journal of the National Cancer Institute 96(13): 986.